1例妊娠期药物暴露风险的药学监护

doi:10.19803/j.1672-8629.20220626

中国药物警戒 ›› 2023, Vol. 20 ›› Issue (8): 933-934.
DOI: 10.19803/j.1672-8629.20220626

1例妊娠期药物暴露风险的药学监护

王然, 李轶凡, 刘小艳, 冯欣^*

首都医科大学附属北京妇产医院,北京妇幼保健院药事部,北京 100026

收稿日期:2022-10-24 出版日期:2023-08-15 发布日期:2023-08-07
通讯作者: ^*冯欣,女,硕士,主任药师,妇产科临床药学。E-mail: fengxin1115@ccmu.edu.cn
作者简介:王然,女,硕士,主管药师,妊娠期用药评价。
基金资助:
北京市自然科学基金青年项目（7224354）; 北京市属医院科研培育计划（PZ2022028）; 北京市医院管理中心临床医学发展专项经费资助(ZYLX202119)

One case of pharmaceutical care of drug exposure during pregnancy

WANG Ran, LI Yifan, LIU Xiaoyan, FENG Xin^*

Beijing Obstetrics and Gynecology Hospital, Beijing Maternal and Child Health care Hospital Affiliated to Capital Medical University, Beijing 100026, China

Received:2022-10-24 Online:2023-08-15 Published:2023-08-07

摘要/Abstract

摘要： 目的探讨围孕期药物暴露特点及妊娠期用药风险,讨论相关药学服务开展的方式及流程。方法通过1例围孕期药物暴露的门诊药学服务,分析意外妊娠喹诺酮类等风险药物的暴露对妊娠可能产生的影响,评价妊娠期过敏性鼻炎的药物治疗风险。结果通过药学问诊收集信息,结合高级别证据个体化分析患者妊娠期用药风险,建议患者可酌情继续妊娠且加强相关超声检查,并针对患者疾病状态进行治疗方案评估,给予过敏性鼻炎用药建议及生活指导。结论药师在评价围孕期药物暴露风险中发挥了重要作用,为患者提供了更为专业化、个体化的药学服务。

关键词: 妊娠期, 药物暴露, 过敏性鼻炎, 用药风险评价, 莫西沙星, 药学监护

Abstract: Objective To explore the characteristics of drug exposure during pregnancy and the risks of drug use during pregnancy, and to study the methods and procedures of pharmaceutical care. Methods The outpatient pharmaceutical care for one case of periconceptional drug exposure was used to analyze the possible impact of exposure to such risk drugs as quinolones during pregnancy, and to evaluate the risk of medication for allergic rhinitis during pregnancy. Results The information was collected through pharmacy consultation, and the risk of medication was analyzed individually with high-level evidence. The pharmacist recommended that the patient continue pregnancy and receive related ultrasound examination. The pharmacist also evaluated the treatment plan according to the patient's conditions and gave advice on treatment of allergic rhinitis. Conclusion Pharmacists can play an important role in evaluating the risk of drug exposure during perinatal pregnancy, and provide more individualized pharmaceutical care for patients.

Key words: pregnancy, drug exposure, allergic rhinitis, risk assessment of medication, moxifloxacin, pharmaceutical care

中图分类号:

R969.4

王然, 李轶凡, 刘小艳, 冯欣. 1例妊娠期药物暴露风险的药学监护[J]. 中国药物警戒, 2023, 20(8): 933-934.

WANG Ran, LI Yifan, LIU Xiaoyan, FENG Xin. One case of pharmaceutical care of drug exposure during pregnancy[J]. Chinese Journal of Pharmacovigilance, 2023, 20(8): 933-934.

参考文献

[1] HUANG H, LI XS, ZHANG J.Analysis of 8408 cases of outpatient medication consultation during pregnancy[J]. Evaluation and Analysis of Drug-Use in Hospitals of China(中国医院用药评价与分析), 2021, 21(5): 616-619.
[2] YI D, ZHANG J, HUANG L.Prescriptions for pregnant outpatients[J]. Chinese Journal of Pharmacovigilance(中国药物警戒), 2020, 17(8): 518-522.
[3] QIAO J, WANG YY, LI XH, et al.A lancet commission on 70 years of women's reproductive, maternal, newborn, child, and adolescent health in China[J]. Lancet, 2021, 397(10293): 2497-2536.
[4] ZHANG J, UNG C, GUAN X, et al.Safety of medication use during pregnancy in mainland China: based on a national health insurance database in 2015[J]. BMC Pregnancy and Childbirth, 2019, 19(1): 459.
[5] HAAS DM, MARSH DJ, DANG DT, et al.Prescription and other medication use in pregnancy[J]. Obstet Gynecol, 2018, 131(5): 789-798.
[6] HOUBEN E, WINKEL BT, STEEGERS EAP, et al.Dutch trends in the use of potentially harmful medication during pregnancy[J]. Br J Clin Pharmacol, 2020, 86(12): 2377-2392.
[7] GAI D, FENG X.New model of pharmaceutical care in drug safety of pregnant women[J]. Practical Pharmacy and Clinical Remedies(实用药物与临床), 2019, 22(11):1121-1124.
[8] TAO J, LI XH, TAN X, et al.Technical specification for consultation on the risk of drug teratogenicity during pregnancy[J]. Chinese Journal of Obstetrics & Gynecology and Pediatrics (Electronic Edition)(中华妇幼临床医学杂志电子版), 2021, 17(4): 393-401.
[9] YUAN M, ZHANG B.Research progress on pregnancy outcomes and related mechanisms of misuse of quinolones in early pregnancy[J]. Chinese Journal of Clinical Pharmacy(中国临床药学杂志), 2021, 30(2) :157-160.
[10] ACAR S, KESKIN-ARSLAN E, EROL-COSKUN H, et al.Pregnancy outcomes following quinolone and fluoroquinolone exposure during pregnancy: a systematic review and meta-analysis[J]. Reproductive Toxicology, 2019, 85: 65-74.
[11] ZIV A, MASARWA R, PERLMAN A, et al.Pregnancy outcomes following exposure to quinolone antibiotics - a systematic-review and meta-analysis[J]. Pharm Res, 2018, 35(5): 109.
[12] SCHAEFER C, PETERS P, MILLER RK.Pregnancy and lactation: treatment options and risk assessment[M]. Pittsburgh: Academic Press, 2015.
[13] BRIGGS GG, TOWERS CV, FORINASH AB.Drugs in pregnancy and lactation: a reference guide to fetal and neonatal risk[M]. 12th ed. Philadelphia : Lippincott Williams& Wilkins(LWW), 2021.
[14] SHEEHY O, SANTOS F, FERREIRA E, et al.The use of metronidazole during pregnancy: a review of evidence[J]. Curr Drug Saf, 2015, 10(2):170-179.
[15] QIN B.Investigation on the safety of metronidazole in pregnant women[D]. Chengdu: University of Electronic Science and Technology of China, 2020.
[16] WORKOWSKI KA, BACHMANN LH, CHAN PA, et al.Sexually transmitted infections treatment guidelines, 2021[J]. MMWR Recomm Rep, 2021, 70(4): 1-187.
[17] BERARD A, SHEEHY O, KURZINGER ML, et al.Intranasal triamcinolone use during pregnancy and the risk of adverse pregnancy outcomes[J]. J Allergy Clin Immunol 2016, 138(1): 96-97.
[18] NAMAZY JA, SCHATZ M.The safety of intranasal steroids during pregnancy: a good start[J]. J Allergy Clin Immunol, 2016, 138(1): 105-106.
[19] Subspecialty Group of Rhinology, Editorial Board of Chinese Journal of Otorhinolaryngology Head and Neck Surgery, Subspecialty Group of Rhinology, Society of Otorhinolaryngology Head and Neck Surgery,Chinese Medical Association. Chinese guideline for diagnosis and treatment of allergic rhinitis (2022, revision)[J]. Chin J Otorhinolaryngol Head Neck Surg(中华耳鼻咽喉头颈外科杂志), 2022, 57(2): 106-129.
[20] CHARLTON RA, SBOWBALL JM, NIGHTINGALE AL, et al. Sagety of fluticasone propionate prescribed for asthma during pregnancy: a UK population-based cohort study[J]. J Allergy Clin Immunol Pract, 2015, 3(5): 772-779. e3.

1例妊娠期药物暴露风险的药学监护

One case of pharmaceutical care of drug exposure during pregnancy

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

[1]	张夏兰, 袁静, 吴斌, 秦媛媛. 甲磺酸阿帕替尼在恶性肿瘤患者的用药特征分析[J]. 中国药物警戒, 2023, 20(8): 927-932.
[2]	刘婧, 夏亮, 张世杰. 1例多元药物过敏急性胰腺炎患者行药物激发试验的药学监护[J]. 中国药物警戒, 2023, 20(7): 822-824.
[3]	王然, 冯欣, 杜博冉. 围孕期妊娠用药暴露风险评价与药学实践进展[J]. 中国药物警戒, 2023, 20(7): 836-840.
[4]	陈崇泽, 李婕, 旷煉, 檀学文, 刘敏惠, 刘熙, 郑燕钗, 靳洪涛. 448例住院患者药物性肝损伤相关不良反应特征分析[J]. 中国药物警戒, 2023, 20(6): 697-704.
[5]	范秀丛, 董晓慧, 陈丹霞, 鲍思蔚, 马雅斌. 1例妊娠期艰难梭菌感染伴尿路感染患者的药学监护[J]. 中国药物警戒, 2023, 20(5): 579-582.
[6]	杨岩, 周德喜, 吴欣俐, 薛淑雅, 丁海华, 张泉, 张云玲. 84例新型抗肿瘤药品不良反应报告分析[J]. 中国药物警戒, 2023, 20(3): 334-338.
[7]	姚鑫, 葛秋格, 李亚敏, 王一帆, 李媛媛, 刘志强. 2018~2022年某院新型抗肿瘤药物消化系统不良反应分析[J]. 中国药物警戒, 2023, 20(11): 1273-1278.
[8]	郑金凤, 王景红. 1例多药联用致室性心律失常的药学监护[J]. 中国药物警戒, 2023, 20(11): 1279-1281.
[9]	苏甦, 伍诗琪, 张青霞, 闫素英. 1例吲达帕胺致粒细胞缺乏症患者的药学监护[J]. 中国药物警戒, 2023, 20(11): 1282-1285.
[10]	王燕婷, 张媛媛, 陈怡然, 孙捷, 朱宇, 杨荔艳, 吴知桂, 申丽君, 程敏, 李国辉. 1例恶性肿瘤患者抗感染与抗肿瘤治疗的平衡抉择及药学监护[J]. 中国药物警戒, 2023, 20(10): 1168-1172.
[11]	王祺茹, 左丽, 杜琼, 叶玲, 阮聪, 翟青, 徐蕊. 1例奥拉帕利致Ⅳ度骨髓抑制患者的药学监护[J]. 中国药物警戒, 2023, 20(10): 1176-1180.
[12]	孙雪林, 张攀, 胡欣. 1例维得利珠单抗治疗重症溃疡性结肠炎的药学监护[J]. 中国药物警戒, 2022, 19(7): 782-785.
[13]	唐静雅. 临床药师参与1例肠外营养相关性肝损伤治疗的药学监护[J]. 中国药物警戒, 2022, 19(7): 786-788.
[14]	李雁铭, 赵志刚. 基于循证的伊布替尼不良反应及药学监护[J]. 中国药物警戒, 2022, 19(7): 807-811.
[15]	刘蕾, 张会娟, 钱效森, 孙瑞芳. 1例磺胺脱敏方案治疗干燥综合征合并卡氏肺孢子菌肺炎的药学监护[J]. 中国药物警戒, 2022, 19(6): 680-683.